 Home > Active Ingredient News > Immunology News > ARD: Baseline Predictors of Treatment Success in Different Types of Rheumatoid Arthritis

ARD: Baseline Predictors of Treatment Success in Different Types of Rheumatoid Arthritis

 Last Update: 2022-01-22
 Source: Internet
 Author: User

Tags

different types antibiotics

reactive protein test

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

OBJECTIVE : Previous studies have demonstrated that lower levels of baseline disease activity predict favorable disease activity status
.
Furthermore, higher levels of baseline disease activity proved to be associated with greater absolute change

ObjectivesObjective : Previous studies have demonstrated that lower levels of baseline disease activity predict favorable disease activity status

Methods : Investigators used data from three rheumatoid arthritis (RA) trials (one for the primary analysis and two for the validation) to analyze patient and disease characteristics, core set measures, and composite index pairs to achieve different outcomes Effects of: response outcome (percentage of patients achieving relative response range); status outcome (remission or low disease activity, LDA ) and change outcome (numerical change on a metric scale)

Methods: Investigators used data from three rheumatoid arthritis (RA) trials (one for primary analysis and two for validation) to analyze differences in patient and disease characteristics, core set measures, and composite indices.

RESULTS: Investigators included patients from the ASPIRE trial (for analysis) and from the ATTRACT and GO-BEFORE trials (for validation)

ConclusionsConclusions : Prediction of success in RA treatment is limited
.

Source:

Capelusnik D, Aletaha D.
Baseline predictors of different types of treatment success in rheumatoid arthritis.
Annals of the Rheumatic Diseases2022; 81: 153-158.

Capelusnik D, Aletaha D.

Baseline predictors of different types of treatment success in rheumatoid arthritis.
Annals of the Rheumatic Diseases2022; 81: 153-158.
Annals of the Rheumatic Diseases81: Leave a comment here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Melatonine 99

CAS No.: 73-31-4

pharmaceutical grade

$100/KG FOB

China Largest Manufacturer Supply High Purity ISOPRINOSINE CAS 36703-88-5

CAS No.: 36703-88-5

Pharmacy Grade

$3-3.5/KG FOB

API Rapamycin Powder 53123-88-9 99% Sirolimus powder

CAS No.: 53123-88-9

Pharmacy Grade

$2-2.5/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.